Jing-Ling Xia
15 Papers
1 Citations
Jing-Ling Xia is an academic researcher. The author has contributed to research in topics: Medicine & Hepatocellular carcinoma. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
A decade's studies on metastasis of hepatocellular carcinoma.
Zhao-You Tang,Sheng-Long Ye,Yinkun Liu,Lun-Xiu Qin,Hui-Chuan Sun,Qin-Hai Ye,Lu Wang,Jian Zhou,Shuang-Jian Qiu,Yan Li,Xue-Ning Ji,Hu Liu,Jing-Ling Xia,Zhi-Quan Wu,Jia Fan,Zeng-Chen Ma,Xin-Da Zhou,Zhi-Ying Lin,Kang-Da Liu +18 more
TL;DR: A molecular signature that can classify metastatic HCC patients is generated, osteopontin is identified as a lead gene in the signature, and it is found that genes favoring metastasis progression were initiated in the primary tumors.
437
Guidelines for Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus in China (2021 Edition)
Ju-Xian Sun,Rong Ping Guo,Xinyu Bi,Mengchao Wu,Zy Tang,Wan Yee Lau,Shusen Zheng,Xuehao Wang,Jin-Ming Yu,Xiaoping Chen,Jia Fan,Jiahong Dong,Yongjun Chen,Yunfu Cui,Chaoliu Dai,Chihua Fang,Shuang Feng,Zhili Ji,Weidong Jia,Ningyang Jia,Gong Li,Jing Li,Qiuyuan Li,Jiangtao Li,Tingbo Liang,Lianxin Liu,Shi-yong Lu,Yi Lv,Yilei Mao,Yan Meng,Zhiqiang Meng,Feng Shen,Jie Shi,Hui-Chuan Sun,Kaishan Tao,Gao-Jun Teng,Xuying Wan,Tian-Fu Wen,Liqun Wu,Jing-Ling Xia,Mingang Ying,Jian Zhai,Leida Zhang,Xuewen Zhang,Zhi-wei Zhang,Haiping Zhao,Donghai Zheng,Xu-Ting Zhi,Jiebai Zhou,Cuncai Zhou,Jian Zhou,Z. Zeng,Kangshun Zhu,Minshan Chen,Jianqiang Cai,Shu-Qun Cheng +55 more
TL;DR: The Chinese Association of Liver Cancer and Chinese Medical Doctor Association revised the 2018 version of the guideline to adapt to the development of PVTT treatment to depend on new evidences from more future clinical trials.
Comprehensive Metabolic Profiling and Genome-wide Analysis Reveal Therapeutic Modalities for Hepatocellular Carcinoma
Feng Qi,Jia Li,Zhuoran Qi,Jian Zhang,Bin Zhou,Biwei Yang,Wenxing Qin,Wenguo Cui,Jing-Ling Xia +8 more
TL;DR: Wang et al. as mentioned in this paper performed multi-omics analysis and cross-cohort validation to investigate the metabolic dysregulation of 562 hepatocellular carcinoma (HCC) patients from 4 cohorts.
26
Loss of GABARAPL1 confers ferroptosis resistance to cancer stem‐like cells in hepatocellular carcinoma
Xiaojing Du,Zhuoran Qi,Jinzhi Xu,Mengzhou Guo,Xingxing Zhang,Zhijie Yu,Xin Cao,Jing-Ling Xia +7 more
TL;DR: A set of ferroptosis‐related stemness genes (FRSG) is identified and it is found that these genes may be involved in immune infiltration in HCC and uncovered a molecular mechanism via which CSLC could achieve tolerance to ferroPTosis.
25
Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)
Yu Rong Yang,Ju-Xian Sun,Mengchao Wu,Wan Yee Lau,Shusen Zheng,Xuehao Wang,Xiaoping Chen,Jia Fan,Jiahong Dong,Jianqiang Cai,Minshan Chen,Yongjun Chen,Zhangjun Cheng,Chaoliu Dai,Jianzhen Shan,Cheng-You Du,Chihua Fang,Heping Hu,Zhili Ji,Wei Jia,Gong Li,Jing Li,Jiangtao Li,Chang Liu,Fu-bao Liu,Yongjie Ma,Yilei Mao,Zuoxing Niu,Jie Shen,Jie Shi,Xuetao Shi,Wenjie Song,Hui-Chuan Sun,Guang Tan,Ran Tao,Xiaohua Wang,Tian-Fu Wen,Liqun Wu,Jing-Ling Xia,Bang-De Xiang,Mao-Hui Yan,Mingang Ying,Ling Zhang,Xuewen Zhang,Zhao-Chong Zeng,Yubao Zhang,Zhiwei Zhang,Jiebai Zhou,Cuncai Zhou,Jun Zou,Ledu Zhou,Xinmin Zhou,Ji Zhu,Zhenyu Zhu,Qi Zhang,Qiu-shi Li,Shu-Qun Cheng +56 more
TL;DR: The consensus contained 17 recommendations, including the preferred regimen for first- and second-line immunotherapy, evaluation and monitoring before/during/after treatment, management of complications, precautions for special patients and potential population for immunotherapy.
15